electroCore, Inc.

Listed Company

ECORCIK 0001560258NasdaqNon-AcceleratedSmaller ReportingElectromedical & Electrotherapeutic ApparatusDelawareGBFY ends Dec 31

Period

FY 2025

Revenue

$32.03M

Net Income

$-14.00M

Total Assets

$18.67M

Equity

$-1.71M

Shares Out

8.30M

Op. Cash Flow

$-8.19M

ECOR$5.93−21.16% · past yearDBEQ Basic

Daily closing prices

Business

electroCore, Inc. is a bioelectronic technology company developing and commercializing non-invasive vagus nerve stimulation devices and wearable neuromodulation platforms. The company markets two principal prescription medical device categories: gammaCore for primary headache conditions (migraine, cluster headache, hemicrania continua) and Quell Fibromyalgia for chronic pain management, as well as consumer wellness products Truvaga and TAC-STIM. electroCore generates revenue through prescription device sales via specialty pharmacies, healthcare systems, and direct distribution; direct-to-consumer e-commerce; and government contracts, primarily with the U.S. Department of Veterans Affairs and UK National Health Service.

Summary from 10-K filed 2026-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	32	25	16	9	5
Cost of goods sold	4	4	3	2	1
Gross profit	28	21	13	7	4
Research and development	3	2	—	—	—
Selling, general and administrative	38	31	27	24	22
Total operating expenses	41	34	32	30	24
Loss from operations	−13	−12	−19	−23	−20
Interest and other income	−298,000	−572,000	−433,000	−287,000	−11,000
Interest expense	590,000	389,000	—	—	—
Other expense	518,000	—	184,000	6,000	8,000
Total other expense (income)	810,000	−183,000	—	—	—
Loss before income taxes	−14	−12	−19	−23	−18
(Provision) benefit from income taxes	−3,000	93,000	186,000	431,000	851,000
Net loss	−14	−12	−19	−22	−17
Net loss per share of common stock - Basic	−1.65	−1.59	−3.42	−4.69	−4.36
Net loss per share of common stock - Diluted	−1.65	−1.59	−3.42	−4.69	−4.36
Weighted average common shares outstanding - Basic	8,483	7,483	6	4,729	3,945
Weighted average common shares outstanding - Diluted	8,483	7,483	6	4,729	3,945

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	7	4	10	18	35
Marketable securities	5	9	—	—	—
Accounts receivable, net	1	1	717,000	401,000	438,000
Inventories	2	2	2	2	1
Prepaid expenses and other current assets	1	1	836,000	828,000	1
Total current assets	16	16	14	21	38
Property and equipment, net	382,000	158,000	204,000	50,000	147,000
Operating lease right-of-use assets, net	3	4	502,000	565,000	613,000
Other assets, net	54,000	274,000	495,000	774,000	591,000
Total assets	19	20	16	25	43
Accounts payable	3	2	2	2	938,000
Accrued expenses and other current liabilities	8	7	6	5	4
Current portion of operating lease liabilities	375,000	361,000	89,000	74,000	61,000
Total current liabilities	11	9	8	7	5
Operating lease liabilities, noncurrent	2	4	537,000	625,000	700,000
Long-term debt	7	—	—	—	—
Total liabilities	20	13	9	8	6
Commitments and contingencies (see Note 16)	—	—	—	—	—
Common Stock, par value $0.001 per share; 500,000,000 shares authorized as of December 31, 2025 and 2024; 8,004,416 shares issued and outstanding at December 31, 2025, and 6,650,854 shares issued and outstanding at December 31, 2024	8,000	7,000	6,000	5,000	5,000
Additional paid-in capital	189	185	173	164	161
Accumulated deficit	−191	−177	−165	−146	−124
Accumulated other comprehensive loss	99,000	114,000	−64,000	−69,000	13,000
Total stockholders equity (deficit)	−2	8	7	17	37
Total liabilities and stockholders equity (deficit)	19	20	16	25	43

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock based compensation	2	2	2	3	3
Depreciation and amortization	501,000	760,000	—	—	—
Amortization of right of use assets	1	498,000	63,000	48,000	—
Amortization of debt discount	135,000	—	—	—	—
Write-down of licensed devices	150,000	—	—	—	—
Inventory reserve charge	41,000	—	682,000	200,000	70,000
Increase in provision for credit losses	523,000	51,000	−54,000	—	49,000
Accounts receivable	−142,000	−710,000	−262,000	37,000	−217,000
Inventories	16,000	713,000	96,000	296,000	371,000
Prepaid expenses and other assets	−294,000	102,000	−8,000	225,000	716,000
Accounts payable	2	1	35,000	1	464,000
Accrued expense and other current liabilities	635,000	831,000	1	356,000	425,000
Operating lease liabilities	−1	−225,000	−73,000	−62,000	20,000
Net cash used in operating activities	−8	−7	−15	−17	−14
Purchase of property and equipment	−66,000	—	−206,000	—	—
Sale (purchase) of marketable securities	4	−9	—	—	—
Net cash provided by (used in) investing activities	4	−9	−206,000	—	18
Sale of common stock and warrants	217,000	8	8	—	26
Issuance of long-term debt	8	—	—	—	—
Debt issuance costs	−95,000	—	—	—	—
Equity issuance costs	−94,000	−232,000	—	—	—
Proceeds from exercise of options	98,000	—	—	—	—
Proceeds from exercise of warrants	1,000	371,000	—	—	—
Net cash provided by financing activities	8	8	7	—	26
Effect of changes in exchange rates on cash and cash equivalents	18,000	147,000	—	—	—
Net decrease in cash and cash equivalents	3	−7	—	—	—
Proceeds from sale of state net operating losses	48,000	122,000	—	445,000	877,000
Interest paid	397,000	13,000	13,000	6,000	10,000
Insurance premium financing	452,000	359,000	361,000	522,000	874,000
Accounts payable settled through common stock and warrants	2	1	—	—	—
Accounts payable settled through the exercise of warrants	495,000	495,000	—	—	—
Non-cash debt issuance costs	213,000	—	—	—	—
Shares issued in connection with Avenue loan	720,000	—	—	—	—
Accrued purchases of property and equipment	203,000	—	—	—	—
Right-of-use asset and operating lease liability	—	3	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is electroCore, Inc.'s CIK number?

electroCore, Inc.'s SEC CIK number is 0001560258 (1560258). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find electroCore, Inc.'s SEC filings?

All of electroCore, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did electroCore, Inc. last report earnings?

electroCore, Inc. (ECOR) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-021493). This is electroCore, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is electroCore, Inc.'s most recent earnings 8-K?

electroCore, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001493152-26-021493. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View electroCore, Inc.'s latest earnings 8-K →
Look up any company's CIK number →